Matinas BioPharma Holdings, Inc.
MTNB- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001582554
No open-market purchases or sales by Matinas BioPharma Holdings, Inc. insiders were filed in the last 90 days; 25 institutions reported holding it in 13F filings for Q2 2026, worth $199.2K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Matinas BioPharma Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Matinas BioPharma Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Stern Adam K | 10% Owner | 743,785Indirect | Aug 13, 2026 | 1 |
| Sanitam Partners LLC | 10% Owner | – | Aug 13, 2026 | 1 |
| Neugeboren Edward | Director | – | May 2, 2025 | 0 |
| D An Evelyn | Director | – | May 2, 2025 | 0 |
| Smith Robin L | Director | – | May 2, 2025 | 0 |
| Murphy Keith | Director | – | May 2, 2025 | 0 |
| Jabbour Jerome D | President and CEO | – | May 2, 2025 | 0 |
| Eide Robert J | 10% Owner | – | Apr 10, 2025 | 0 |
| Pembroke & Partners LLC | 10% Owner | – | Apr 10, 2025 | 0 |
| Matkovits Theresa | Chief Development Officer | – | Dec 15, 2023 | 0 |
| Kucinski Keith A | Chief Financial Officer | – | Dec 15, 2023 | 0 |
| Ferguson James J. III | Chief Medical Officer | – | Dec 15, 2023 | 0 |
| Hui Liu | Chief Technology Officer | – | Dec 15, 2023 | 0 |
| Hoover Thomas | Chief Business Officer | – | Dec 15, 2023 | 0 |
| Wikler Matthew | Director | 290,472 | Nov 3, 2023 | 0 |
| Conrad Herbert J | Director | 4,694,566Indirect | Nov 3, 2023 | 0 |
| Giordano Natasha | Director | – | Nov 3, 2023 | 0 |
| Scibetta James S | Director | – | Nov 3, 2023 | 0 |
| Ende Eric J | Director | – | Nov 3, 2023 | 0 |
| Corzo Kathryn Penkus | Director | – | Nov 3, 2023 | 0 |
| Mannino Raphael J | Chief Scientific Officer | 1,919,715 | Dec 15, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 10, 2025 (view filing) | Apr 8 | 2 days | Sanitam Partners LLC10% Owner | PPurchase | +3.60M | $0.586 | +$703.0K | –4.80M after | AmendedDerivative2 lots |
| Apr 10, 2025 (view filing) | Apr 8 | 2 days | Eide Robert J10% Owner | PPurchase | +2.52M | $0.586 | +$492.0K | –3.36M after | AmendedDerivative2 lotsDuplicate filing |
| Apr 10, 2025 (view filing) | Apr 8 | 2 days | Pembroke & Partners LLC10% Owner | PPurchase | +2.52M | $0.586 | +$492.0K | –3.36M after | AmendedDerivative2 lots |